HELSINKI, June 12, 2013 /CNW/ - Blueprint Genetics has launched a new
genetic testing technology for professional use in hospitals. The gene
sequencing technology is based on Stanford University research and can
effectively analyse rare hereditary human diseases. The company started
its operations in 2012 in Helsinki.
The tests of Blueprint Genetics enable efficient diagnosis of difficult
hereditary diseases. Today there are almost 4000 recognized diseases
with a genetic background. The results of genetic tests will help
physicians in reaching their diagnoses, predicting the course of the
disease, choosing treatments, and efficient screening of relatives. The
first tests of Blueprint Genetics focus on hereditary cardiovascular
The company aims to bring genetic diagnostics into the daily routines of
healthcare organizations by lowering the barrier to start using genetic
testing. This will be enabled by offering tests that are more
comprehensive, more cost-effective and faster than existing tests. The
geneticists and clinicians at Blueprint Genetics will interpret the
test results and give statements directly to the treating physicians
within three weeks from sample reception.
Blueprint Genetics targets international diagnostics markets and will
begin its operations in the EU area. The international recommendations
for the use of genetic diagnostics are increasing rapidly and current
research advocates comprehensive testing for hereditary diseases.
According to Blueprint Genetics, there have never been so
comprehensive, or easy-to-use tests available for a price level that is
feasible for clinical use.
The company has a strong background in medical genetics research.
"Finland is a great place to start an international genetics growth
company. We have a huge amount of knowledge and resources in Finland
and the genetics research is globally recognized," says Tommi Lehtonen,
CEO of Blueprint Genetics.
Blueprint Genetics provides advanced professional genetic testing for
rare diseases. The company started its operations in 2012 and provides
diagnostics for cardiovascular, neurological and eye disorders.
Currently the company employs 11 employees and is based in Helsinki,
SOURCE: Blueprint Genetics
For further information:
Blueprint Genetics Oy